Loading
Three FRα ADCs carry different poisons (tubulin, hemiasterlin, topoisomerase). Use them in sequence rather than treating them as interchangeable.
Three folate receptor alpha antibody-drug conjugates in ovarian cancer share an antigen but not a payload: mirvetuximab soravtansine carries the tubulin agent DM4 and is used only in FRalpha-high tumours, luveltamab tazevibulin carries a hemiasterlin, and rinatabart sesutecan carries the topoisomerase 1 inhibitor exatecan. The idea is to sequence them by payload class rather than treating them as interchangeable. The rationale is that resistance to a tubulin payload, through tubulin mutations or efflux, is not expected to cross to a topoisomerase payload, and FRalpha is rarely lost at progression. The test would be a post-mirvetuximab cohort of RAINFOL-02 or a phase 2 with paired biopsies; the evidence is preclinical, and the idea connects to the general rule of payload-class switching.
Folate receptor alpha testing is now standard in platinum-resistant ovarian cancer and mirvetuximab is the preferred treatment for high-expressing tumours, with an eye-care protocol.
One of the most cited trial reports Europe PMC returns for Mirvetuximab soravtansine in Ovarian cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Mirvetuximab soravtansine in Ovarian cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer, Folate receptor alpha, Mirvetuximab soravtansine, Platinum-resistant ovarian cancer.
Shares Rinatabart sesutecan, Folate receptor alpha, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Folate receptor alpha, Mirvetuximab soravtansine, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Mirvetuximab soravtansine, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Luveltamab tazevibulin, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Luveltamab tazevibulin, Folate receptor alpha, Ovarian cancer.
Shares Rinatabart sesutecan, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Rinatabart sesutecan, Platinum-resistant ovarian cancer, Ovarian cancer.